Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program
Susan E. Prockop(Memorial Sloan Kettering Cancer Center), Sarah Nikiforow(Otsuka (Japan)), Willis H. Navarro(University of California, San Francisco), Wen‐Kai Weng(Stanford University), Donald E. Tsai(University of Pennsylvania), Eneida R. Nemecek(Oregon Health & Science University), David M. Loeb(Albert Einstein College of Medicine), Koen van Besien(University Hospitals of Cleveland), Kris M. Mahadeo(Duke University), Minoti Hiremath(Yale University), Ran Reshef(Abramson Cancer Center), Sunita D. Nasta(University of Pennsylvania), Yan Sun(Shanghai Jiao Tong University), Rolla Abu‐Arja(Nationwide Children's Hospital), Susan Yue(Atara Biotherapeutics (United States)), Nancy Bunin(University of Iowa)
Cited by 9
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k